Analysis looks at early experience with REBYOTA in clinical practice Additional analyses evaluate efficacy and safety of REBYOTA in patients…
Parsippany, NJ – October 3, 2023 – Ferring Pharmaceuticals today announced it will present two analyses of data for REBYOTA® (fecal…
Fortune’s “Change the World” List recognises companies that have had a positive social impact through activities that are part of…
Parsippany, NJ – September 21, 2023 – Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA® (fecal microbiota,…
Urologists treating eligible high-risk bladder cancer patients at participating early experience program clinics in the U.S. can now prescribe the…
Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on…
Integrated analysis is the largest safety evaluation to date of any microbiota-based live biotherapeutic and includes safety data for up…
Parsippany, NJ – June 26, 2023 – Ferring Pharmaceuticals today announced it will make the intravesical gene-therapy ADSTILADRIN® (nadofaragene firadenovec-vncg) available…
Approval of Prior-Approval Supplement will help to ensure the future, long-term supply and clinical activities for Ferring’s novel intravesical gene…
The primary endpoint was met: SI-6603 showed statistically significant improvement in worst leg pain score versus control at 13 weeks…